Gamma-decanolactone: Preliminary evaluation as potential antiparkinsonian drug
| Autor: | José Angel Fontenla, Amit Kumar, Patrícia Pereira, María Isabel Loza, Dolores Viña, Pricila Pflüger, José Brea |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Monoamine Oxidase Inhibitors Reserpine Monoamine oxidase Drug Evaluation Preclinical Pharmacology Permeability Antiparkinson Agents Lactones Mice Structure-Activity Relationship 03 medical and health sciences 0302 clinical medicine In vivo medicine Animals Humans Parkinson Disease Secondary Monoamine Oxidase IC50 Enzyme Assays Benserazide Chemistry Receptors Purinergic P1 Parkinson Disease Hep G2 Cells Ligand (biochemistry) Adenosine receptor Recombinant Proteins In vitro Molecular Docking Simulation Disease Models Animal 030104 developmental biology Blood-Brain Barrier Docking (molecular) 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | European Journal of Pharmacology. 906:174276 |
| ISSN: | 0014-2999 |
| DOI: | 10.1016/j.ejphar.2021.174276 |
| Popis: | Treatment of Parkinson's disease (PD) includes the use of monoamine oxidase-B (MAO-B) inhibitor drugs. In this work we have evaluated the possible gamma-decanolactone (GD) effect in vitro to inhibit the A and B isoforms of human monoamine oxidase (hMAO) enzyme and their citotoxicity in human hepatoma cell line (HepG2). Also, binding studies to A1, A2A A2B and A3 adenosine receptors were performed. A docking study of gamma-decanolactone has been carried out with the molecular targets of MAO-A and MAO-B isoforms. The physicochemical properties and ability to cross physiological barriers, as the blood brain barrier (BBB), was elucidated by computational studies. The in vivo assays, the rota-rod test, body temperature assessment and open field test were performed in reserpinized mice (1.5 mg/kg, i.p.; 18:00 before) to evaluate the effect of gamma-decanolactone (300 mg/kg), alone or associated with Levodopa plus Benserazide (LD + BZ, 100:25 mg/kg, i.p.). Gamma-decanolactone inhibited preferentially the MAO-B in a reversible manner, with an inhibitory concentration of 50% (IC50) 55.95 ± 9.06 μM. It was shown to be a safe drug since only at the highest concentration decreased the viability of HepG2 cells. It also does not bind to adenosine receptors investigated in this study. The molecular docking study show that the gamma-decanolactone ligand adopts a relatively compact conformation in the active site of hMAO-B, while we note an extended conformation of gamma-decanolactone ligand in the hMAO-A isoform. The physicochemical properties obtained, and the theoretical models utilized for the evaluation of ability to cross the BBB, predict a good gamma-decanolactone bioavailability and access to the central nervous system (CNS). In the in vivo studies, gamma-decanolactone partially reversed the ataxia of the reserpinized mice at 01:00 h and 01:30 h post-administration. Concomitant treatment of gamma-decanolactone with LD + BZ, at 01:30 h showed a potentiation of the reversibility of ataxia and facilitated the reversal of hypothermia caused by reserpine for all measured times (P In summary, the results herein obtained and in conjunction with previous studies, suggest that gamma-decanolactone could be a drug with potential utility as antiparkinsonian drug. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect